Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822797 | 0.91 | PPARG (0.46) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL7836787 | 0.87 | PPARG (0.47) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL7833143 | 0.87 | PPARG (0.47) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL7834333 | 0.87 | PPARG (0.50) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL7837681 | 0.83 | PPARG (0.46) | PPARGFFAR1PPARAESRRA | |
| SCHEMBL7823746 | 0.83 | PPARG (0.46) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL7835328 | 0.82 | PPARG (0.47) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL7835053 | 0.82 | PPARG (0.46) | PPARGFFAR1PPARAESRRA | |
| SCHEMBL7831920 | 0.82 | PPARG (0.47) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL7834794 | 0.82 | PPARG (0.44) | PPARGFFAR1PPARAESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |